OncoMatch/Clinical Trials/NCT06158386
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Is NCT06158386 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Chidamide combined with Linperlisib for follicular lymphoma.
Treatment: Chidamide combined with Linperlisib — To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody — first-line
at least one of the first-line treatments includes anti-CD20 monoclonal antibody (anti-CD20 monoclonal antibody monotherapy or combined chemotherapy)
Cannot have received: PI3K inhibitor
Exception: disease has progressed during the treatment period (within 6 months after the last use)
Any PI3K inhibitor has been used before and the disease has progressed during the treatment period (within 6 months after the last use)
Cannot have received: systemic anti-tumor therapy
Received systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment
Cannot have received: radiotherapy
Received systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment
Cannot have received: hematopoietic stem cell transplantation
Exception: within 3 months before enrollment
The patients received the transplantation of somatic hematopoietic stem cells within 3 months before enrollment
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: within 6 months before drug administration or any active graft-versus-host disease
Patients received allogeneic hematopoietic stem cell transplantation or had any active graft-versus-host disease within 6 months before drug administration
Lab requirements
Blood counts
neutrophils < 1.5× 10^9/L, HB < 80 g/L, PLT < 75×10^9 /L
Kidney function
glomerular filtration rate (eGFR) < 30 ml/min
Liver function
serum total bilirubin > 1.5 x ULN or serum ALT and AST > 2.5x ULN; with liver infiltration by lymphoma, AST and ALT > 5x ULN
Cardiac function
all kinds of clinically significant abnormal rhythm or conduction; Hereditary QT interval syndrome or QTcF>480 msec or taking drugs that may cause QT interval delay or torsade de pointes; acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months; NYHA grade 3 or above; LVEF <40%; uncontrolled blood pressure (Systolic > 160 mmHg or diastolic > 100 mmHg)
Impaired bone marrow function: neutrophils < 1.5× 10^9/L, HB < 80 g/L, PLT < 75×10^9 /L, Impaired liver function, defined as serum total bilirubin > 1.5 x ULN or serum ALT and AST > 2.5x ULN, Patients with liver infiltration by lymphoma, AST and ALT > 5x ULN, Renal glomerular filtration rate (eGFR) < 30 ml/min. PT INR>1.5ULN or APTT> 1.5 ULN, Serum amylase or lipase > 1ULN. ... all kinds of clinically significant abnormal rhythm or conduction need clinical pre-diagnosis Hereditary QT interval syndrome or QTcF>480 msec or taking drugs that may cause Qt interval delay or torsade de pointes. A variety of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months of the group, with New York's cardiology (NYHA) classification of grade 3 or above. Left ventricular ejection fraction (LVEF )<40%, or uncontrolled blood pressure controlled by drugs (Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mgHg).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify